血管內(nèi)皮生長因子B(VEGFB)多克隆抗體
Polyclonal Antibody to Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 編號PAA144Bo02
- 物種Bos taurus; Bovine (Cattle,牛) 相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPA144Bo02-血管內(nèi)皮生長因子B(VEGFB)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性狀液體
- 濃度0.5mg/ml
- 且適物種-
- 應用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術(shù),請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 680 ¥ 1588 ¥ 2268 ¥ 5670 ¥ 22680
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對VEGFB的兔多克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別VEGFB。
用法
Western blotting: 0.5-2μg/mL
Immunohistochemistry: 5-20μg/mL
Immunocytochemistry: 5-20μg/mL
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務
相關產(chǎn)品
編號 | 適用物種:Bos taurus; Bovine (Cattle,牛) | 應用(僅供研究使用,不用于臨床診斷!) |
RPA144Bo02 | 血管內(nèi)皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA144Bo01 | 血管內(nèi)皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA144Bo01 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
PAA144Bo02 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
參考文獻
雜志 | 參考文獻 |
International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379] |
Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033] |
Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z] |
EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [] |
Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713] |
留言咨詢